Li Wuping, Zhong Yun, Shuang Yuerong, Huang Hui, Huang Yan, Yu Li, Huang Xianbao
Lymphoma and Myeloma Department, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, China.
Hermatology Department, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330029, China.
Cancer Biomark. 2017 Aug 23;20(2):159-164. doi: 10.3233/CBM-170054.
Lymphoma associated hemophagocytic syndrome (LAHS) is one of the major adult secondary hemophagocytic lymphohistiocytosis (HLH). Early diagnosis and treatment contribute to improved outcome. No enlarge lymph nodes can often delay the diagnosis of underlying lymphoma.
To find out criteria distinguishing LAHS from HLH induced by benign diseases.
clinical characteristic and laboratory feature of 31 patients with HLH (10 benign disease-associated HLH and 21 LAHS) were analyzed retrospectively.
No significantly differences were observed in the levels of LDH, IL-6, IL-10, TNF-α; however, the level of CRP (C reactive protein) and the mean level of sIL-R (soluble interleukin-2 receptor) were higher in patients with LAHS than those with benign disease associated disease associated HLH while ferritin levels were higher in benign disease associated HLH than in LAHS. Consequently, the serum sIL-2R/ferritin ratio of patients with LAHS was markedly higher than that of patients with benign disease associated HLH (0.33 ± 0.23 vs 5.82 ± 3.26, P= 0.0001). In addition, we found out that the mean level of miR-133 (microRNA-133) was significant higher in LAHS than in benign disease associated HLH (18.83 ± 10.44 vs 5.82 ± 3.26, P⩽ 0.0001).
Serum miR-133 is a new very useful marker for diagnosing of LAHS, but it need further confirmation by further clinical studies.
淋巴瘤相关噬血细胞综合征（LAHS）是成人继发性噬血细胞性淋巴组织细胞增生症（HLH）的主要类型之一。早期诊断和治疗有助于改善预后。无肿大淋巴结常常会延误潜在淋巴瘤的诊断。
找出区分LAHS与良性疾病所致HLH的标准。
回顾性分析31例HLH患者（10例良性疾病相关HLH和21例LAHS）的临床特征和实验室检查结果。
乳酸脱氢酶（LDH）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）水平差异无统计学意义；然而，LAHS患者的C反应蛋白（CRP）水平和可溶性白细胞介素-2受体（sIL-R）平均水平高于良性疾病相关HLH患者，而良性疾病相关HLH患者的铁蛋白水平高于LAHS患者。因此，LAHS患者的血清sIL-2R/铁蛋白比值明显高于良性疾病相关HLH患者（0.33±0.23对5.82±3.26，P=0.0001）。此外，我们发现LAHS患者的微小RNA-133（miR-133）平均水平显著高于良性疾病相关HLH患者（18.83±10.44对5.82±3.26，P≤0.0001）。
血清miR-133是诊断LAHS的一种新型且非常有用的标志物，但需要进一步的临床研究予以进一步证实。
